Prostaglandin e2 inhibits IFN-α secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement

Journal of Immunology

Volumn 184, Issue 2, 2010, Pages 677-684

  Fabricius, Dorit ^a   Neubauer, Marina ^a   Mandel, Birgit ^a   Schütz, Catharina ^a   Viardot, Andreas ^a   Vollmer, Angelika ^a   Jahrsdörfer, Bernd ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; B7 ANTIGEN; CD86 ANTIGEN; CORTISONE; CYCLOSPORIN A; FLUOCORTOLONE; HYDROXYCHLOROQUINE SULFATE; INTERFERON REGULATORY FACTOR 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTANOID E RECEPTOR 2; PROSTANOID E RECEPTOR 4; PROSTANOID RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE; PROSTAGLANDIN EP2 RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SOFT TISSUE INFLAMMATION; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; CASE CONTROL STUDY; DENDRITIC CELL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SECRETION;

CASE-CONTROL STUDIES; CYTOKINES; DENDRITIC CELLS; DINOPROSTONE; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, PROSTAGLANDIN E; TH1 CELLS;

EID: 76249092889     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902028     Document Type: Article

References (55)

1. Gilliet, M.,W. Cao, and Y. J. Liu. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8: 594-606.
2. Liu, Y. J. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23: 275-306.
3. Brown, K. N., A. Trichel, and S. M. Barratt-Boyes. 2007. Parallel loss of myeloid and plasmacytoid dendritic cells from blood and lymphoid tissue in simian AIDS. J. Immunol. 178: 6958-6967.
4. Smit, J. J., D. M. Lindell, L. Boon, M. Kool, B. N. Lambrecht, and N.W. Lukacs. 2008. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE 3:e1720.
5. Colonna, M., G. Trinchieri, and Y. J. Liu. 2004. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5: 1219-1226.
6. Fitzgerald-Bocarsly, P., J. Dai, and S. Singh. 2008. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 19: 3-19.
7. Rönnblom, L., M. L. Eloranta, and G. V. Alm. 2003. Role of natural interferon-α producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 36: 463-472.
8. Waldner, H. 2009. The role of innate immune responses in autoimmune disease development. Autoimmun. Rev. 8: 400-404.
9. Farkas, L., K. Beiske, F. Lund-Johansen, P. Brandtzaeg, and F. L. Jahnsen. 2001. Plasmacytoid dendritic cells (natural interferon- α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159: 237-243.
10. Cavanagh, L. L., A. Boyce, L. Smith, J. Padmanabha, L. Filgueira, P. Pietschmann, and R. Thomas. 2005. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res. Ther. 7: R230-R240.
11. Smolewska, E., J. Stańczyk, H. Brózik, M. Biernacka-Zielińska, B. Cebula, T. Robak, and P. Smolewski. 2008. Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis. Ann. Rheum. Dis. 67: 762-768.
12. Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
13. Pascual, V., L. Farkas, and J. Banchereau. 2006. Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol. 18: 676-682.
14. Rönnblom, L., and V. Pascual. 2008. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17: 394-399.
15. Phipps, R. P., S. H. Stein, and R. L. Roper. 1991. A new view of prostaglandin E regulation of the immune response. Immunol. Today 12: 349-352.
16. Smith, W. L., L. J. Marnett, and D. L. DeWitt. 1991. Prostaglandin and thromboxane biosynthesis. Pharmacol. Ther. 49: 153-179.
17. Coleman, R. A., W. L. Smith, and S. Narumiya. 1994. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46: 205-229.
18. Jonuleit, H., U. Kühn, G. Müller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142.
19. Kubo, S., H. K. Takahashi, M. Takei, H. Iwagaki, T. Yoshino, N. Tanaka, S. Mori, and M. Nishibori. 2004. E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization. J. Pharmacol. Exp. Ther. 309: 1213-1220.
20. Akaogi, J., T. Nozaki, M. Satoh, and H. Yamada. 2006. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr. Metab. Immune Disord. Drug Targets 6: 383-394.
21. Hilkens, C. M., A. Snijders, H. Vermeulen, P. H. van der Meide, E. A. Wierenga, and M. L. Kapsenberg. 1996. Accessory cell-derived IL-12 and prostaglandin E2 determine the IFN-γ level of activated human CD4+ T cells. J. Immunol. 156: 1722-1727.
22. Kaliński, P., P. L. Vieira, J. H. Schuitemaker, E. C. de Jong, and M. L. Kapsenberg. 2001. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97: 3466-3469.
23. Walt,R. P. 1992. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N. Engl. J. Med. 327: 1575-1580.
24. Karetova, D., J. Bultas, V. Vondracek, and M. Aschermann. 1997. Alprostadil: modes of actions in peripheral arterial occlusive disease. Am. J. Ther. 4: 359-363.
25. Fabricius, D., M. S. O'Dorisio, S. Blackwell, and B. Jahrsdörfer. 2006. Human plasmacytoid dendritic cell function: inhibition of IFN-α secretion and modulation of immune phenotype by vasoactive intestinal peptide. J. Immunol. 177: 5920-5927. (Pubitemid 44628805)
26. Duramad, O., K. L. Fearon, J. H. Chan, H. Kanzler, J. D. Marshall, R. L. Coffman, and F. J. Barrat. 2003. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 102: 4487-4492.
27. Nataraj, C., D. W. Thomas, S. L. Tilley, M. T. Nguyen, R. Mannon, B. H. Koller, and T. M. Coffman. 2001. Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J. Clin. Invest. 108: 1229-1235.
28. Yao, C., D. Sakata, Y. Esaki, Y. Li, T. Matsuoka, K. Kuroiwa, Y. Sugimoto, and S. Narumiya. 2009. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15: 633-640.
29. Hung, C. H., Y. T. Chu, J. L. Suen, M. S. Lee, H. W. Chang, Y. C. Lo, and Y. J. Jong. 2009. Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2 analogues. Eur. Respir. J. 33: 405-410.
30. Son, Y., T. Ito, Y. Ozaki, T. Tanijiri, T. Yokoi, K. Nakamura, M. Takebayashi, R. Amakawa, and S. Fukuhara. 2006. Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. Immunology 119: 36-42.
31. Wu, P., J. Wu, S. Liu, X. Han, J. Lu, Y. Shi, J. Wang, L. Lu, and X. Cao. 2008. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin. Immunol. 129: 40-48.
32. Asano, T., J. Shoda, T. Ueda, T. Kawamoto, T. Todoroki, M. Shimonishi, T. Tanabe, Y. Sugimoto, A. Ichikawa, M. Mutoh, et al. 2002. Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin. Cancer Res. 8: 1157-1167.
33. Rissoan, M. C., V. Soumelis, N. Kadowaki, G. Grouard, F. Briere, R. de Waal Malefyt, and Y. J. Liu. 1999. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183-1186. (Pubitemid 129504124)
34. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
35. Becker, Y. 2006. Molecular immunological approaches to biotherapy of human cancers - a review, hypothesis and implications. Anticancer Res. 26(2A): 1113-1134.
36. García-Sastre, A., and C. A. Biron. 2006. Type 1 interferons and the virus-host relationship: a lesson in détente. Science 312: 879-882.
37. Pestka, S., C. D. Krause, and M. R. Walter. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202: 8-32.
38. Roura, M., F. Lopez-Gil, and P. Umbert. 1991. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica 182: 56-58.
39. Hoshi, K., and S. Fukuhara. 2008. Effect of Lipo-PGE1 on health-related quality of life in patients with systemic sclerosis and systemic lupus erythematosus in Japan. J. Int. Med. Res. 36: 187-197.
40. Ooiwa, H., T. Miyazawa, Y. Yamanishi, K. Hiyama, S. Ishioka, and M. Yamakido. 2000. Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue. Intern. Med. 39: 320-323.
41. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2: 523-532.
42. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174: 915-924.
43. Delgado, M., E. Gonzalez-Rey, and D. Ganea. 2005. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J. Immunol. 175: 7311-7324. (Pubitemid 41713427)
44. Gonzalez-Rey, E., A. Chorny, A. Fernandez-Martin, D. Ganea, and M. Delgado. 2006. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107: 3632-3638.
45. Moseman, E. A., X. Liang, A. J. Dawson, A. Panoskaltsis-Mortari, A. M. Krieg, Y. J. Liu, B. R. Blazar, and W. Chen. 2004. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 173: 4433-4442.
46. Cella, M., F. Facchetti, A. Lanzavecchia, and M. Colonna. 2000. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 1: 305-310.
47. Cheon, H., Y. H. Rho, S. J. Choi, Y. H. Lee, G. G. Song, J. Sohn, N. H. Won, and J. D. Ji. 2006. Prostaglandin E2 augments IL-10 signaling and function. J. Immunol. 177: 1092-1100.
48. Namazi, M. R. 2004. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int. Immunopharmacol. 4: 349-353.
49. Cruchaud, A., J. P. Despont, A. Roth, and J. M. Dayer. 1984. Phagocytosis, bactericidal capacity, and PGE2 production of monocytes in systemic lupus erythematosus and rheumatoid arthritis. Diagn. Immunol. 2: 203-212.
50. Eloranta, M. L., T. Lövgren, D. Finke, L. Mathsson, J. Rönnelid, B. Kastner, G. V. Alm, and L. Rönnblom. 2009. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 60: 2418-2427.
51. Chae, B. S., T. Y. Shin, D. K. Kim, J. S. Eun, J. Y. Leem, and J. H. Yang. 2008. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice. Arch. Pharm. Res. 31: 503-510.
52. Baechler, E. C., P. K. Gregersen, and T.W. Behrens. 2004. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16: 801-807.
53. Fairhurst, A. M., A. Mathian, J. E. Connolly, A. Wang, H. F. Gray, T. A. George, C. D. Boudreaux, X. J. Zhou, Q. Z. Li, S. Koutouzov, et al. 2008. Systemic IFN-α drives kidney nephritis in B6.Sle123 mice. Eur. J. Immunol. 38: 1948-1960.
54. Banchereau, J., V. Pascual, and A. K. Palucka. 2004. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20: 539-550.
55. Bengtsson, A. A., G. Sturfelt, L. Truedsson, J. Blomberg, G. Alm, H. Vallin, and L. Rönnblom. 2000. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9: 664-671.